U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C31H33N3O6S
Molecular Weight 575.675
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ZAFIRLUKAST

SMILES

COC1=C(CC2=CN(C)C3=C2C=C(NC(=O)OC4CCCC4)C=C3)C=CC(=C1)C(=O)NS(=O)(=O)C5=C(C)C=CC=C5

InChI

InChIKey=YEEZWCHGZNKEEK-UHFFFAOYSA-N
InChI=1S/C31H33N3O6S/c1-20-8-4-7-11-29(20)41(37,38)33-30(35)22-13-12-21(28(17-22)39-3)16-23-19-34(2)27-15-14-24(18-26(23)27)32-31(36)40-25-9-5-6-10-25/h4,7-8,11-15,17-19,25H,5-6,9-10,16H2,1-3H3,(H,32,36)(H,33,35)

HIDE SMILES / InChI

Molecular Formula C31H33N3O6S
Molecular Weight 575.675
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020547s027lbl.pdf

Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Zafirlukast is indicated for the prophylaxis and chronic treatment of asthma. Patients with asthma were found in one study to be 25-100 times more sensitive to the bronchoconstricting activity of inhaled LTD4 than nonasthmatic subjects. In vitro studies demonstrated that zafirlukast antagonized the contractile activity of three leukotrienes (LTC4, LTD4 and LTE4) in conducting airway smooth muscle from laboratory animals and humans. Zafirlukast prevented intradermal LTD4-induced increases in cutaneous vascular permeability and inhibited inhaled LTD4-induced influx of eosinophils into animal lungs. Zafirlukast is a selective and competitive receptor antagonist of leukotriene D4 and E4 (LTD4 and LTE4), components of slow-reacting substance of anaphylaxis (SRSA). Cysteinyl leukotriene production and receptor occupation have been correlated with the pathophysiology of asthma, including airway edema, smooth muscle constriction, and altered cellular activity associated with the inflammatory process, which contribute to the signs and symptoms of asthma. Zafirlukast is marketed by Astra Zeneca with the brand names Accolate, Accoleit, and Vanticon. It was the first LTRA to be marketed in the USA and is now approved in over 60 countries, including the UK, Japan, Taiwan, Italy, Spain, Canada, Brazil, China and Turkey.

CNS Activity

Curator's Comment: Studies in rats using radiolabeled Zafirlukast indicate minimal distribution across the blood-brain barrier.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ACCOLATE

Approved Use

ACCOLATE is indicated for the prophylaxis and chronic treatment of asthma in adults and children 5 years of age and older.

Launch Date

1996
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
352.7 ng/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZAFIRLUKAST plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1090.41 ng × h/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZAFIRLUKAST plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.3 h
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZAFIRLUKAST plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
20 mg 2 times / day multiple, oral
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy, 12-76
n = 514
Health Status: unhealthy
Condition: asthma, mild-to-moderate
Age Group: 12-76
Sex: M+F
Population Size: 514
Sources:
Other AEs: Pharyngitis, Headache...
Other AEs:
Pharyngitis (24.7%)
Headache (13.8%)
Myalgia (3.7%)
Sinusitis (3.5%)
Flu syndrome (3.3%)
Cough increased (3.1%)
Rash (3.1%)
Rhinitis (3.1%)
Accidental injury (3.1%)
Nausea (3.1%)
Back pain (2.9%)
Hypertonia (2.9%)
Diarrhea (2.7%)
Exacerbation of asthma (2.7%)
Sources:
20 mg 2 times / day multiple, oral
Highest studied dose
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy, 37
n = 67
Health Status: unhealthy
Condition: asthma, moderate
Age Group: 37
Sex: M+F
Population Size: 67
Sources:
Other AEs: Headache, Gastritis...
Other AEs:
Headache (7%)
Gastritis (1%)
Pharyngitis (20%)
Rhinitis (7%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Headache 13.8%
20 mg 2 times / day multiple, oral
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy, 12-76
n = 514
Health Status: unhealthy
Condition: asthma, mild-to-moderate
Age Group: 12-76
Sex: M+F
Population Size: 514
Sources:
Diarrhea 2.7%
20 mg 2 times / day multiple, oral
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy, 12-76
n = 514
Health Status: unhealthy
Condition: asthma, mild-to-moderate
Age Group: 12-76
Sex: M+F
Population Size: 514
Sources:
Exacerbation of asthma 2.7%
20 mg 2 times / day multiple, oral
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy, 12-76
n = 514
Health Status: unhealthy
Condition: asthma, mild-to-moderate
Age Group: 12-76
Sex: M+F
Population Size: 514
Sources:
Back pain 2.9%
20 mg 2 times / day multiple, oral
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy, 12-76
n = 514
Health Status: unhealthy
Condition: asthma, mild-to-moderate
Age Group: 12-76
Sex: M+F
Population Size: 514
Sources:
Hypertonia 2.9%
20 mg 2 times / day multiple, oral
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy, 12-76
n = 514
Health Status: unhealthy
Condition: asthma, mild-to-moderate
Age Group: 12-76
Sex: M+F
Population Size: 514
Sources:
Pharyngitis 24.7%
20 mg 2 times / day multiple, oral
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy, 12-76
n = 514
Health Status: unhealthy
Condition: asthma, mild-to-moderate
Age Group: 12-76
Sex: M+F
Population Size: 514
Sources:
Accidental injury 3.1%
20 mg 2 times / day multiple, oral
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy, 12-76
n = 514
Health Status: unhealthy
Condition: asthma, mild-to-moderate
Age Group: 12-76
Sex: M+F
Population Size: 514
Sources:
Cough increased 3.1%
20 mg 2 times / day multiple, oral
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy, 12-76
n = 514
Health Status: unhealthy
Condition: asthma, mild-to-moderate
Age Group: 12-76
Sex: M+F
Population Size: 514
Sources:
Nausea 3.1%
20 mg 2 times / day multiple, oral
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy, 12-76
n = 514
Health Status: unhealthy
Condition: asthma, mild-to-moderate
Age Group: 12-76
Sex: M+F
Population Size: 514
Sources:
Rash 3.1%
20 mg 2 times / day multiple, oral
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy, 12-76
n = 514
Health Status: unhealthy
Condition: asthma, mild-to-moderate
Age Group: 12-76
Sex: M+F
Population Size: 514
Sources:
Rhinitis 3.1%
20 mg 2 times / day multiple, oral
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy, 12-76
n = 514
Health Status: unhealthy
Condition: asthma, mild-to-moderate
Age Group: 12-76
Sex: M+F
Population Size: 514
Sources:
Flu syndrome 3.3%
20 mg 2 times / day multiple, oral
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy, 12-76
n = 514
Health Status: unhealthy
Condition: asthma, mild-to-moderate
Age Group: 12-76
Sex: M+F
Population Size: 514
Sources:
Sinusitis 3.5%
20 mg 2 times / day multiple, oral
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy, 12-76
n = 514
Health Status: unhealthy
Condition: asthma, mild-to-moderate
Age Group: 12-76
Sex: M+F
Population Size: 514
Sources:
Myalgia 3.7%
20 mg 2 times / day multiple, oral
Recommended
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy, 12-76
n = 514
Health Status: unhealthy
Condition: asthma, mild-to-moderate
Age Group: 12-76
Sex: M+F
Population Size: 514
Sources:
Gastritis 1%
20 mg 2 times / day multiple, oral
Highest studied dose
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy, 37
n = 67
Health Status: unhealthy
Condition: asthma, moderate
Age Group: 37
Sex: M+F
Population Size: 67
Sources:
Pharyngitis 20%
20 mg 2 times / day multiple, oral
Highest studied dose
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy, 37
n = 67
Health Status: unhealthy
Condition: asthma, moderate
Age Group: 37
Sex: M+F
Population Size: 67
Sources:
Headache 7%
20 mg 2 times / day multiple, oral
Highest studied dose
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy, 37
n = 67
Health Status: unhealthy
Condition: asthma, moderate
Age Group: 37
Sex: M+F
Population Size: 67
Sources:
Rhinitis 7%
20 mg 2 times / day multiple, oral
Highest studied dose
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
unhealthy, 37
n = 67
Health Status: unhealthy
Condition: asthma, moderate
Age Group: 37
Sex: M+F
Population Size: 67
Sources:
PubMed

PubMed

TitleDatePubMed
[Zafirlukast therapy of patients with mild-to-moderate bronchial asthma].
1999 Jun 13
Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor.
1999 Sep
Discovery of CP-199,330 and CP-199,331: two potent and orally efficacious cysteinyl LT1 receptor antagonists devoid of liver toxicity.
1999 Sep 20
Efficacy and duration of action of the antileukotriene zafirlukast on cold air-induced bronchoconstriction.
2000 Apr
Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids.
2000 Aug
Severe liver injury after treatment with the leukotriene receptor antagonist zafirlukast.
2000 Dec 19
[Zafirlukast inhibition of leukotriene C4 induced endothelin-1 expression in human airway structural cell].
2000 Oct
Addition of anti-leukotriene agents to inhaled corticosteroids for chronic asthma.
2001
Pharmacology of airway afferent nerve activity.
2001
Cost-efficacy analysis of fluticasone propionate versus zafirlukast in patients with persistent asthma.
2001
A comparison of short-term treatment with inhaled fluticasone propionate and zafirlukast for patients with persistent asthma.
2001 Aug 15
Allergy and angiitis: two aspects of Churg-Strauss syndrome.
2001 Feb
Asthma outcome changes associated with use of the leukotriene-receptor antagonist zafirlukast.
2001 Feb
One-year claims analysis comparing inhaled fluticasone propionate with zafirlukast for the treatment of asthma.
2001 Jan
The role of antileukotrienes in the treatment of asthma.
2001 Jun
Role of cysteinyl leukotrienes in nociceptive and inflammatory conditions in experimental animals.
2001 Jun 29
Antileukotrienes in asthma: present situation.
2001 Mar
Efficacy of zafirlukast in the treatment of patients with bronchial asthma.
2001 Mar
The effect of low-dose inhaled fluticasone propionate on exhaled nitric oxide in asthmatic patients and comparison with oral zafirlukast.
2001 Oct
Acute hepatocellular injury associated with zafirlukast.
2001 Oct
Zafirlukast-related hepatitis: report of a further case.
2001 Oct
[Leukotriene modifiers].
2001 Oct
Leukotriene receptor antagonists in the treatment of allergic rhinitis.
2001 Oct
Chronic asthma.
2001 Oct 27
An open study to evaluate the safety and efficacy of zafirlukast ("Accolate") in patients with mild to moderate asthma in Ibadan, Nigeria.
2001 Oct-Dec
Effects of zafirlukast upon clinical, physiologic, and inflammatory responses to natural cat allergen exposure.
2001 Sep
Fulminant eosinophilic endomyocarditis in an asthmatic patient treated with pranlukast after corticosteroid withdrawal.
2001 Sep
Pharmacokinetic profile of zafirlukast.
2002
Pharmacogenetics of asthma.
2002 Apr 1
[Reflections on antileukotrienes].
2002 Apr 15
[Churg-Strauss syndrome after treatment with Singulair (montelukast)].
2002 Feb 20
[Study on relationship between leukotrienes and exercise-induced asthma].
2002 Jan 10
Efficacy and safety of low-dose fluticasone propionate compared with zafirlukast in patients with persistent asthma.
2002 Jul
Antitussive effect of the leukotriene receptor antagonist zafirlukast in subjects with cough-variant asthma.
2002 Jun
Treatment of canine atopic dermatitis with zafirlukast, a leukotriene-receptor antagonist: a single-blinded, placebo-controlled study.
2002 Mar
Inhaled fluticasone and zafirlukast in persistent asthma.
2002 Mar
Comparison of second controller medications in addition to inhaled corticosteroid in patients with moderate asthma.
2002 May
[New horizons in the treatment of atopic dermatitis].
2002 May-Jun
Patents

Sample Use Guides

Should be taken at least 1 hour before or 2 hours after meals. Adults and Children 12 years of age and older The recommended dose of ACCOLATE in adults and children 12 years and older is 20 mg twice daily. Pediatric Patients 5 through 11 years of age The recommended dose of ACCOLATE in children 5 through 11 years of age is 10 mg twice daily.
Route of Administration: Oral
In Vitro Use Guide
Zafirlukast significantly inhibited 10 uM LTD4-evoked 35SO4 output in a concentration-dependent fashion, with maximal inhibition of 78% at 10 uM zafirlukast, and IC50 value of 0.6 uM.
Substance Class Chemical
Created
by admin
on Sat Dec 16 17:43:31 GMT 2023
Edited
by admin
on Sat Dec 16 17:43:31 GMT 2023
Record UNII
XZ629S5L50
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ZAFIRLUKAST
INN   JAN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
ZAFIRLUKAST [MART.]
Common Name English
Cyclopentyl 3-[2-methoxy-4-[(O-tolylsulfonyl)carbamoyl]benzyl]-1-methylindole-5-carbamate
Common Name English
ZAFIRLUKAST [USAN]
Common Name English
ICI-204,219
Common Name English
ICI 204,219
Code English
ICI-204219
Code English
Zafirlukast [WHO-DD]
Common Name English
ZAFIRLUKAST [MI]
Common Name English
ACCOLATE
Brand Name English
ZAFIRLUKAST [VANDF]
Common Name English
ZAFIRLUKAST [ORANGE BOOK]
Common Name English
zafirlukast [INN]
Common Name English
ZAFIRLUKAST [JAN]
Common Name English
CARBAMIC ACID, (3-((2-METHOXY-4-(((2-METHYLPHENYL)SULFONYL)AMINO)CARBONYL)PHENYL)METHYL)-1-METHYL-1H-INDOL-5-YL)-, CYCLOPENTYL ESTER
Common Name English
Classification Tree Code System Code
NDF-RT N0000175777
Created by admin on Sat Dec 16 17:43:32 GMT 2023 , Edited by admin on Sat Dec 16 17:43:32 GMT 2023
NDF-RT N0000000083
Created by admin on Sat Dec 16 17:43:32 GMT 2023 , Edited by admin on Sat Dec 16 17:43:32 GMT 2023
NCI_THESAURUS C29712
Created by admin on Sat Dec 16 17:43:32 GMT 2023 , Edited by admin on Sat Dec 16 17:43:32 GMT 2023
LIVERTOX NBK547915
Created by admin on Sat Dec 16 17:43:32 GMT 2023 , Edited by admin on Sat Dec 16 17:43:32 GMT 2023
WHO-ATC R03DC01
Created by admin on Sat Dec 16 17:43:32 GMT 2023 , Edited by admin on Sat Dec 16 17:43:32 GMT 2023
WHO-VATC QR03DC01
Created by admin on Sat Dec 16 17:43:32 GMT 2023 , Edited by admin on Sat Dec 16 17:43:32 GMT 2023
Code System Code Type Description
SMS_ID
100000091929
Created by admin on Sat Dec 16 17:43:32 GMT 2023 , Edited by admin on Sat Dec 16 17:43:32 GMT 2023
PRIMARY
CAS
107753-78-6
Created by admin on Sat Dec 16 17:43:32 GMT 2023 , Edited by admin on Sat Dec 16 17:43:32 GMT 2023
PRIMARY
USAN
GG-93
Created by admin on Sat Dec 16 17:43:32 GMT 2023 , Edited by admin on Sat Dec 16 17:43:32 GMT 2023
PRIMARY
MERCK INDEX
m11576
Created by admin on Sat Dec 16 17:43:32 GMT 2023 , Edited by admin on Sat Dec 16 17:43:32 GMT 2023
PRIMARY Merck Index
INN
7244
Created by admin on Sat Dec 16 17:43:32 GMT 2023 , Edited by admin on Sat Dec 16 17:43:32 GMT 2023
PRIMARY
FDA UNII
XZ629S5L50
Created by admin on Sat Dec 16 17:43:32 GMT 2023 , Edited by admin on Sat Dec 16 17:43:32 GMT 2023
PRIMARY
EVMPD
SUB00128MIG
Created by admin on Sat Dec 16 17:43:32 GMT 2023 , Edited by admin on Sat Dec 16 17:43:32 GMT 2023
PRIMARY
ChEMBL
CHEMBL603
Created by admin on Sat Dec 16 17:43:32 GMT 2023 , Edited by admin on Sat Dec 16 17:43:32 GMT 2023
PRIMARY
NCI_THESAURUS
C47785
Created by admin on Sat Dec 16 17:43:32 GMT 2023 , Edited by admin on Sat Dec 16 17:43:32 GMT 2023
PRIMARY
PUBCHEM
5717
Created by admin on Sat Dec 16 17:43:32 GMT 2023 , Edited by admin on Sat Dec 16 17:43:32 GMT 2023
PRIMARY
IUPHAR
3322
Created by admin on Sat Dec 16 17:43:32 GMT 2023 , Edited by admin on Sat Dec 16 17:43:32 GMT 2023
PRIMARY
DRUG BANK
DB00549
Created by admin on Sat Dec 16 17:43:32 GMT 2023 , Edited by admin on Sat Dec 16 17:43:32 GMT 2023
PRIMARY
EPA CompTox
DTXSID5023746
Created by admin on Sat Dec 16 17:43:32 GMT 2023 , Edited by admin on Sat Dec 16 17:43:32 GMT 2023
PRIMARY
LACTMED
Zafirlukast
Created by admin on Sat Dec 16 17:43:32 GMT 2023 , Edited by admin on Sat Dec 16 17:43:32 GMT 2023
PRIMARY
WIKIPEDIA
ZAFIRLUKAST
Created by admin on Sat Dec 16 17:43:32 GMT 2023 , Edited by admin on Sat Dec 16 17:43:32 GMT 2023
PRIMARY
DRUG CENTRAL
2855
Created by admin on Sat Dec 16 17:43:32 GMT 2023 , Edited by admin on Sat Dec 16 17:43:32 GMT 2023
PRIMARY
MESH
C062735
Created by admin on Sat Dec 16 17:43:32 GMT 2023 , Edited by admin on Sat Dec 16 17:43:32 GMT 2023
PRIMARY
RXCUI
114970
Created by admin on Sat Dec 16 17:43:32 GMT 2023 , Edited by admin on Sat Dec 16 17:43:32 GMT 2023
PRIMARY RxNorm
DAILYMED
XZ629S5L50
Created by admin on Sat Dec 16 17:43:32 GMT 2023 , Edited by admin on Sat Dec 16 17:43:32 GMT 2023
PRIMARY
CHEBI
10100
Created by admin on Sat Dec 16 17:43:32 GMT 2023 , Edited by admin on Sat Dec 16 17:43:32 GMT 2023
PRIMARY
NDF-RT
N0000185504
Created by admin on Sat Dec 16 17:43:32 GMT 2023 , Edited by admin on Sat Dec 16 17:43:32 GMT 2023
PRIMARY Cytochrome P450 2C9 Inhibitors [MoA]
Related Record Type Details
BINDER->LIGAND
BINDING
TARGET -> INHIBITOR
METABOLIC ENZYME -> SUBSTRATE
MAJOR
METABOLIC ENZYME -> INHIBITOR
in vitro studies utilizing human liver microsomes show that zafirlukast inhibits the cytochrome P450 CYP3A4 and CYP2C9 isoenzymes at concentrations close to the clinically achieved total plasma concentrations.
METABOLIC ENZYME -> INHIBITOR
in vitro studies utilizing human liver microsomes show that zafirlukast inhibits the cytochrome P450 CYP3A4 and CYP2C9 isoenzymes at concentrations close to the clinically achieved total plasma concentrations
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Route of Elimination PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
Cmax PHARMACOKINETIC Populations
PHARMACOKINETIC
Route of Elimination PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
Cmax PHARMACOKINETIC Populations
PHARMACOKINETIC
Tmax PHARMACOKINETIC
Onset of Action PHARMACOKINETIC